Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 295-442-6
CAS number: 92045-60-8
A complex combination of hydrocarbons obtained by subjecting a petroleum naphtha to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C5, predominantly C5, and boiling in the range of approximately minus 10°C to 35°C (14°F to 95°F).
The acute toxicity of members of the low boiling point naphtha category has been investigated in a large number of animal studies (44 oral/dermal and 38 inhalation). Around 20 individual CAS RNs from the category have been tested, and the acute toxicity can be summarised as follows:
Acute toxicity – Oral LD50 > 5000 mg/kg (OECD TG 401)
Acute toxicity – Dermal LD50 > 2000 mg/kg (OECD TG 402 under occlusive conditions)
Acute toxicity – Inhalation LC50 > 5610 mg/m3 (OECD TG 403)
The acute toxicity of members of the low
boiling point naphtha category has been investigated in a large number
of animal studies (44 oral/dermal and 38 inhalation). Around 20
individual CAS RNs from the category have been tested and show similar
result, summarised as follows:
Acute toxicity – Oral LD50 > 5000 mg/kg
(OECD TG 401)
Acute toxicity – Dermal LD50 > 2000
mg/kg (OECD TG 402 under occlusive conditions)
Acute toxicity – Inhalation LC50 > 5610
mg/m3 (OECD TG 403)
Human evidence also indicates that
gasoline has very low acute oral, dermal or inhalation toxicity. However,
it can produce severe injury if taken into the lung as a liquid, and
there may be profound central nervous system depression following
prolonged exposure to high levels of vapor. Laboratory animals respond
similarly to humans. Neither gasoline itself, nor any of the naphtha
blending stocks produces acute oral, dermal or inhalation toxicity under
conditions defined by regulatory testing protocols.
Justification for selection of acute toxicity – oral endpoint
one of a large number of studies showing LD50 > 5000 mg/kg
Justification for selection of acute toxicity – inhalation endpoint
one of a large number of acute studies by the inhalation route
Justification for selection of acute toxicity – dermal endpoint
one of a number of studies showing acute dermal LD50 > 2000 mgkg
Although most of these studies were
conducted many years ago, they were generally, conducted in accordance
with regulatory guidelines good laboratory practice recommendations. The
data are this considered adequate for regulatory purposes and no
additional testing is warranted.
The data do not meet the criteria for
hazard classification for acute, dermal or inhalation toxicity according
to EU CLP Regulation (EC No. 1272/2008);
however, warnings for aspiration hazard and potential narcotic effects
at high concentrations should be considered.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again